The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (Ductal carcinoma in situ)

Cancer

Volumn 80, Issue 9, 1997, Pages 1740-1745

  Gupta, Sanjeev K ^a   Douglas Jones, Anthony G ^a   Fenn, Neil ^a   Morgan, J Michael ^a   Mansel, Robert E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Breast; Classification; Ductal carcinoma of the breast; Nottingham prognostic index

Indexed keywords

ARTICLE; BREAST CARCINOMA; BREAST DYSPLASIA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CARCINOMA IN SITU; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; FOLLOW-UP STUDIES; HUMANS; PROGNOSIS;

EID: 0030707679     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971101)80:9<1740::AID-CNCR7>3.0.CO;2-I     Document Type: Article

References (25)

1. Morrow M. The natural history of ductal carcinoma in situ: implications for clinical decision making. Cancer 1995; 76:1113-5.
2. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
3. van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, et al. Ductal carcinoma in situ of the breast. Second EORTC Consensus Meeting. Eur J Cancer 1992; 28:626-9.
4. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
5. Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-7.
6. Poller DN, Silverstein MJ, Galea MH, Locker AP, Elston CW, Blarney RW, Ellis IO. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification, association between cellular proliferation and c-erb B2 protein expression. Mod Pathol 1994;7:257-62.
7. Bellamy CO, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993;24:16-23.
8. Poller DN, Ellis IO. Ductal carcinoma in situ (DCIS) of the breast In: Kirkham N, Lemoine NR, editors. Progress in pathology. Volume 2. Edinburgh: Churchill Livingstone, 1995:47-87.
9. Bobrow LG, Happerfield LC, Gregory WM, Springall RD, Millis RR. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994;11:199-207.
10. Zafrani B, Leroyer A, Fourquet A, Laurent M, Trophilme U, Validire P, et al. Mammographically detected ductal carcinoma in situ carcinoma of the breast analysed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erb B2 proteins and proliferative activity. Semin Diagn Pathol 1994;11:208-14.
11. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987;56:489-92.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991;19:403-10.
13. Steeg PS, Clare SE, Lawrence JA, Zhou Q. Molecular analysis of premalignant and carcinoma in situ lesions of the human breast. Am J Pathol 1996;149:733-8.
14. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erb B-2 protein. Cancer 1995;75:2123-31.
15. Pallis L, Wilking N, Cedermark B, Retquist LE, Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 1992;12:2113-5.
16. Poller DN, Snead DRJ, Roberts EC, Galea M, Bell JA, Gilmour A, et al. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erb B2 oncoprotein. Br J Cancer 1993;68:156-61.
17. Locker AP, Horrocks C, Gilmour AS, Ellis IO, Dowle CS, Elston CW, et al. Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg 1990;77:564-7.
18. Patchefsky AS, Schwartz GF, Finkelstein SD, Prestipino A, Sohn SE, Singer JS, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
19. Fisher ER, Constantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathological findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: intraductal carcinoma (ductal carcinoma in situ). Cancer 1995;75:1310-9.
20. Jensen RA, Dupont WD, Page DL. Diagnostic criteria and cancer risk of proliferative breast lesions. J Cell Biochem 1993;17:59-64.
21. Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992;70(6 Suppl):1727-31.
22. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995;175:195-201.
23. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovanik I, et al. Pattern of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 1990;46:839-44.
24. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hvperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-5.
25. Rosenberg CL, Larson PS, Romo ID, De Las Morenas A, Faller DV. Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 1997;28:214-9.